The Evolving Modern Management of Brain Metastasis
Peter E. Fecci(University of Colorado Anschutz Medical Campus), John H. Sampson(Duke University), Courtney McKernan(Duke University), Ann Marie Pendergast(Duke University), C. Rory Goodwin(Duke Medical Center), Jacob P. Hoj(Duke University), Carey K. Anders(Duke University), John P. Kirkpatrick(Duke University), Cosette D. Champion(Duke University)
Cited by 121
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984